Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke

Tissue plasminogen activator (tPA) is the only US Food and Drug Administration (FDA)–approved drug for ischemic stroke. However, delayed tPA administration is associated with increased risk of blood-brain barrier (BBB) disruption and hemorrhagic transformation (HT). Interferon-β (IFNβ), an FDA-appro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Kuo, Ping-Chang, Weng, Wen-Tsan, Scofield, Barbara A., Furnas, Destin, Paraiso, Hallel C., Intriago, Alexander J., Bosi, Kristopher D., Yu, I-Chen, Yen, Jui-Hung
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Thrombosis and Hemostasis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509872/
https://ncbi.nlm.nih.gov/pubmed/32926126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001443
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars